These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35359767)

  • 1. China's COVID-19 Control Strategy and Its Impact on the Global Pandemic.
    Ding D; Zhang R
    Front Public Health; 2022; 10():857003. PubMed ID: 35359767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. China's COVID-19 Vaccination Strategy and Its Impact on the Global Pandemic.
    Meng Z; Shan S; Zhang R
    Risk Manag Healthc Policy; 2021; 14():4649-4655. PubMed ID: 34815726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. China's Public Health Policies in Response to COVID-19: From an "Authoritarian" Perspective.
    Gao J; Zhang P
    Front Public Health; 2021; 9():756677. PubMed ID: 34976920
    [No Abstract]   [Full Text] [Related]  

  • 4. Implementation and challenges to preventing the re-establishment of malaria in China in the COVID-19 era.
    Lu G; Cao Y; Zhang D; Zhang Y; Xu Y; Lu Y; Chen Q; Zhu G; Yan J; Müller O; Cao J
    Global Health; 2022 Jun; 18(1):64. PubMed ID: 35729642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. China's global engagement to fight the novel coronavirus pandemic.
    Song W
    Glob Health Res Policy; 2020; 5():44. PubMed ID: 33083550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [COVID-19 pandemic: global epidemiological trends and China's subsequent preparedness and responses].
    Guo Y; Huang YM; Huang J; Jin YZ; Jiang W; Liu PL; Liu FJ; Ma JX; Ma JY; Wang Y; Xie Z; Yin H; Zhao CS; Zhou SD; Zhang J; Zheng ZJ;
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 May; 41(5):642-647. PubMed ID: 32164401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research on the Integration of Cultural Tourism Industry Driven by Digital Economy in the Context of COVID-19-Based on the Data of 31 Chinese Provinces.
    Li X; Liang X; Yu T; Ruan S; Fan R
    Front Public Health; 2022; 10():780476. PubMed ID: 35356017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, Status Quo, and Challenges to China's Health Informatization During COVID-19: Evaluation and Recommendations.
    Huang M; Wang J; Nicholas S; Maitland E; Guo Z
    J Med Internet Res; 2021 Jun; 23(6):e27345. PubMed ID: 34061761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of China's public health system response to COVID-19.
    Zhang P; Gao J
    J Glob Health; 2021 Jan; 11():05004. PubMed ID: 33643637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 emergencies around the globe: China's experience in controlling COVID-19 and lessons learned.
    Jin H; Lu L; Liu J; Cui M
    Int J Qual Health Care; 2021 Feb; 33(1):. PubMed ID: 33320189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfolding the Determinants of COVID-19 Vaccine Acceptance in China.
    Yin F; Wu Z; Xia X; Ji M; Wang Y; Hu Z
    J Med Internet Res; 2021 Jan; 23(1):e26089. PubMed ID: 33400682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Digital Economy on the Provision Efficiency for Public Health Services: Empirical Study of 31 Provinces in China.
    Lyu Y; Peng Y; Liu H; Hwang JJ
    Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From blanket quarantine in Wuhan to distant centralized quarantine in Shijiazhuang: the evolution of China's COVID-19 quarantine approach.
    Wang B; Zheng H
    Infection; 2021 Aug; 49(4):765-767. PubMed ID: 33961272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. China's community-based crisis management model for COVID-19: A zero-tolerance approach.
    Shangguan Z; Wang MY
    Front Public Health; 2022; 10():880479. PubMed ID: 35937237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discussion on China's anti-epidemic response based on the Protocol on Prevention and Control of Coronavirus Disease 2019 from Chinese Authority.
    Zhao Z; Zhou Y; Li W; Fan X; Huang Q; Tang Z; Li H; Wang J; Li J; Wu J
    Int J Health Plann Manage; 2022 May; 37(3):1205-1220. PubMed ID: 35064592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of China's Hubei control strategy for COVID-19 epidemic: an observational study.
    Liu Y; Zheng F; Du Z; Li J; Gu J; Jiang M; Yoneoka D; Gilmour S; Hao Y
    BMC Infect Dis; 2021 Aug; 21(1):820. PubMed ID: 34399697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public Health Measures and the Control of COVID-19 in China.
    Cheng ZJ; Zhan Z; Xue M; Zheng P; Lyu J; Ma J; Zhang XD; Luo W; Huang H; Zhang Y; Wang H; Zhong N; Sun B
    Clin Rev Allergy Immunol; 2023 Feb; 64(1):1-16. PubMed ID: 34536214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.
    Liang CK; Lee WJ; Peng LN; Meng LC; Hsiao FY; Chen LK
    Clin Geriatr Med; 2022 Aug; 38(3):605-620. PubMed ID: 35868676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. China's zero-COVID strategy: what happens next?
    Mallapaty S
    Nature; 2022 Feb; 602(7895):15-16. PubMed ID: 35087249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.